Capstone Investments Starts ViroPharma (VPHM) at Buy; High Growth Orphan Drug Company
Tweet Send to a Friend
Capstone Investments initiates coverage on ViroPharma (NASDAQ: VPHM) with a Buy. PT $21.
Capstone analyst says, "The company has successfully ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Capstone analyst says, "The company has successfully ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
